Evidence map›Paper›PMID 42687198›Full record

ArticleExperimental hematology & oncology2026

Single-cell mapping of thymus-dependent naïve t-cell regeneration reveals CD61-associated states after hematopoietic stem cell transplantation.

Fangqing Zhang, Xinya Jiang, Shuang Fan, Bixia Wang, Zhigui Wu, Jingrui Zhou, Qi Zhang, Zhiyu Zhang, Jianing Tang, Zheng-Li Xu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fangqing ZhangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Xinya JiangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Shuang FanBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Bixia WangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Zhigui WuBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Jingrui ZhouBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Qi ZhangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Zhiyu ZhangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Jianing TangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Zheng-Li XuBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Yu WangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China.
Xiao-Jun HuangBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China. xjhrm@medmail.com.cn.
Huidong GuoBeijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Peking University, No. 11 Xizhimen South Street, Beijing, 100044, China. guohuidong@bjmu.edu.cn.

Funding

National Natural Science Foundation of China 82293630National Natural Science Foundation of China 82570265the Beijing Natural Science Foundation General Project 7252142
6 · The paper itself

Abstract

Thymus-dependent de novo T-cell generation is essential for maintaining T-cell diversity and immune competence. Although thymic involution after puberty reduces thymic output, residual thymic function remains important for immune surveillance and immune reconstitution following hematopoietic stem cell transplantation (HSCT). However, the cellular features that distinguish thymus-derived naïve T cells from those maintained through peripheral homeostatic expansion remain poorly understood. Here, we employed a congenic GFP-labeled mouse transplantation model combined with longitudinal single-cell transcriptomic and T-cell receptor repertoire analyses to define the origin and dynamics of naïve T-cell regeneration after HSCT. By distinguishing thymus-derived de novo generated T cells from peripherally expanded T cells, we found that recent thymic emigrants and both CD4⁺ and CD8⁺ naïve T cells preferentially reconstitute through a thymus-dependent pathway. We further identified distinct naïve T-cell states enriched within the thymus-derived compartment, including CD61-associated and Ly6C-associated naïve T-cell states. These populations displayed dynamic changes during immune reconstitution and were associated with thymic functional status in transplantation and physiological thymic involution mouse models. In human datasets and primary peripheral blood samples, CD61-associated features correlated with age-related thymic activity, sjTREC levels, and preliminary measures of thymic recovery after allogeneic HSCT. Collectively, our study defines cellular features of thymus-dependent naïve T-cell regeneration after HSCT and identifies CD61-associated naïve T-cell states as candidate peripheral features linked to thymic recovery. These findings provide new insights into thymus-dependent immune reconstitution and establish a framework for evaluating peripheral signatures of thymic regeneration after HSCT.

Indexed as

CD61Hematopoietic stem cell transplantationLy6CRecent thymic emigrantsThymus-dependent naïve T cell reconstitution

Identifiers

PMID42687198
PMCPMC13536736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.